Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

56%

5 trials in Phase 3/4

Results Transparency

43%

3 of 7 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 3

3(37.5%)

Phase 4

2(25.0%)

N/A

2(25.0%)

Phase 1

1(12.5%)

8Total

Phase 3(3)

Phase 4(2)

N/A(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT04563988Completed

Factors for Predicting Severe Asthma Exacerbators in Adult Asthmatics: A Real Word- Effectiveness Study

Role: collaborator

NCT02834663Phase 4Completed

Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy

Role: collaborator

NCT01380288Not ApplicableCompleted

Cognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After Rivastigmine

Role: collaborator

NCT00942864Phase 3Completed

Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO)

Role: lead

NCT00967213Phase 3Completed

Combination of Ranibizumab and Verteporfin Therapy in Neovascular Age-related Macular Degeneration

Role: lead

NCT00939900Phase 3Completed

Efficacy of Zoledronic Acid in Preventing Collapse of the Osteonecrotic Femoral Head

Role: collaborator

NCT02063269Not ApplicableUnknown

Brain Changes by Rivastigmine According to Butyrylcholinesterase Alleles

Role: collaborator

NCT02427295Phase 4Unknown

Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues

Role: collaborator

NCT01325181Phase 1Completed

Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy

Role: collaborator

All 9 trials loaded